1V-LSD Facts
Psychedelic;
Description
1V-LSD (1-valeroyl-lysergic acid diethylamide) — also known as Valerie — is a synthetic psychedelic of the lysergamide class. Once converted, it activates serotonin receptors in the brain, producing the visual and cognitive shifts characteristic of classical psychedelics.[1]
Subjective effects include geometric visual patterns, color enhancement, time alteration, thought acceleration, and ego dissolution. The experience mirrors LSD — a long-arc, all-encompassing shift in perception and emotion with a characteristic electric body feel.
1V-LSD produces no physical dependence, and LSD — its active metabolite — has no established lethal dose in humans.[2] The primary risk is psychological: high doses can trigger acute panic or psychotic breakdown, and the danger scales with dose and personal vulnerability.[1]
Dose and durationby route · individual sensitivity varies
Starts in 20 – 60 minLasts 8 – 12 hoursAfter-effects 6 – 24 hours
Body and dependence
- Acute toxicity
- Negligible
- Chronic toxicity
- Negligible
- Physical dependence
- None
- Psychological dependence
- Negligible
- Withdrawal
- None recorded
- Compulsive redosing
- Negligible
Tolerance
- Builds
- Rapid
- Fully resets after
- 14 days
- Carries over to
- LSD;
psilocybin; mescaline; DMT; 2C-B
Effectslikely at a common dose
- Perception
- Auditory enhancement;
Color enhancement; Visual drifting; Color alteration; Music enhancement; Environmental patterning; Geometry; Holotropic state; Visual breathing; +29 possible, including Spatial disorientation, Vestibular distortion, Visual haze / noise - Body
- Wakefulness;
Stimulation; Spontaneous body sensations; Pupil dilation; Body high; Body scan awareness; Insomnia; +27 possible, including Muscle tension, Heart rate perception changes, Excessive sweating - Thinking
- Conceptual thinking;
Novelty enhancement; Aesthetic enhancement; Cognitive flexibility; Introspection enhancement; Openness enhancement; Thought connectivity; +28 possible, including Suggestibility enhancement, Memory suppression, Thought loops - Feeling
- Emotional enhancement;
Emotional lability; +8 possible, including Anxiety, Paranoia, Dysphoria - Self
- none likely · 12 possible, including Derealization, Depersonalization, Ego inflation
- Time
- Time alteration;
+4 possible, including Temporal disorientation - Transpersonal
- none likely · 1 possible
- Awareness
- Personal insight;
+7 possible
Who shouldn't take it
Combinations60 recorded
Seek help immediately if
Most difficulty is psychological (intense fear, panic, confusion) and passes with calm support — the signs below mean seek emergency help:
- Very high body temperature; hot, dry skin
- Seizures
- Chest pain; fast or irregular heartbeat
- Severe muscle rigidity, tremor, or twitching (possible serotonin syndrome)
- Cold, pale, or blue fingers/toes — severe vasoconstriction (notably NBOMe / DOx)
- Persistent vomiting; unconsciousness; uncontrollable agitation or risk of self-harm
What to do
- Stay calm and reassure — remind them they took a drug and the effect will pass
- Move to a calm, quiet, safe space with low light; reduce noise and sensory input
- Keep them from harm — they may act on fear or confusion; stay with them, don't leave them alone
- Talk them down gently; don't grab or restrain unless they're in danger
- For the medical signs above (overheating, seizure, chest pain, vasoconstriction, unresponsive) call emergency services
- If overheating, cool the body; be ready to give rescue breaths / CPR
The experience is time-limited and usually resolves with calm reassurance in a safe setting — psychological first aid, not medication. Serious physical harm is uncommon for classic psychedelics (LSD, psilocybin) but real for some potent phenethylamines (NBOMe, DOx), where hyperthermia, seizures, and vasoconstriction warrant emergency care.
988 Suicide & Crisis LifelineFireside Project: 62-FIRESIDE
References
- [1]^abHolze F, Vizeli P, Müller F, Ley L, Duerig R, Varghese N, Zizzari P, Liechti ME (2021) Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects — Neuropsychopharmacology doi:10.1038/s41386-020-00883-6
- [2]^Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A (2008) The pharmacology of lysergic acid diethylamide: a review — CNS Neuroscience and Therapeutics doi:10.1111/j.1755-5949.2008.00059.x